Regimen Name: Pa clitaxel, carboplatin, and trastuzumab Origin of Name: The regimen is named for the 3 drugs it contains.
INDICATIONS
The paclitaxel, carboplatin, and trastuzumab regimen has been studied in locally advanced [5] [6] [7] and metastatic HER2+ breast cancer. 3, [8] [9] [10] [11] Current guidelines recommend it for the treatment of HER2+ recurrent or metastatic breast cancer. 12
CARBOPLATIN DOSE CALCULATION
Carboplatin doses are commonly calculated using an equation based on the method of Calvert et al. 13 Calvert's group showed that the carboplatin dose in milligrams can be calculated using a desired area under the time versus concentration curve (AUC) and the patient's glomerular fi ltration rate (GFR). Calvert measured GFR by clearance of chromium-51-EDTA. The equation is: carboplatin dose (mg) = AUC x [GFR + 25] .
If radiopharmaceutical clearance is not used to measure GFR, creatinine clearance (CrCl) estimated by the Cockcroft-Gault method 14 is commonly used to estimate GFR. Appropriate patient weight and serum creatinine should be used when estimating GFR for use in the Calvert equation. The following guidelines are recommended:
1. If the patient is not obese (body mass index [BMI] < 25) , actual body weight should be used. 15, 16 2. If the patient is overweight or obese (BMI ≥ 25) , an adjusted body weight (ABW) should be used. 17 3. I f the patient has a serum creatinine less than 0.8 mg/dL, round the serum creatinine up to 0.8 mg/dL. 20, 21 The Gynecologic Oncology Group has suggested rounding values less than 0.7 mg/dL up to 0.7 mg/dL. 22 5. Solutions diluted in NS are reported to be stable for up to 28 days at room temperature or refrigerated. 6. The manufacturer recommends that diluted solutions be used within 24 hours. 26 7. Since the provided diluent (BWFI) contains a preservative, partially used vials may be stored under refrigeration (2°C -8°C [36°F -46°F]) for up to 28 days. 
DRUG ADMINISTRATION

SUPPORTIVE CARE
A. The paclitaxel, carboplatin, and trastuzumab regimen is predicted to cause acute emesis in 30% to 90% of patients. [27] [28] [29] [30] The studies reviewed reported mild to moderate (grade 1 or 2) vomiting in 35% of patients and severe vomiting (grade 3) in 5% to 8% of patients. 3, 9 No grade 4 vomiting was reported in any of the studies reviewed. 3, 7, 9 Mild nausea (grade 1 or 2) was experienced by 33% of patients, while severe nausea (grade 3 or 4) was experienced by 8% to 13% of patients, respectively. 3, 9 Although carboplatin is reported to cause delayed nausea or emesis similar to cisplatin, the mechanism of action and clinical course of carboplatin-induced nausea and vomiting differ from cisplatin. 31, 32 Analysis of urinary 5-hydroxyindole acetic acid (5-HIAA) excretion indicates that carboplatin causes a lower peak level, but more prolonged release, of serotonin than cisplatin. The clinical course of carboplatin-induced emesis refl ects this pattern of serotonin release. Carboplatin-induced emesis usually begins 6 to 7 hours after drug administration and may persist for up to 120 hours. Although not well documented in the literature, some clinicians divide the daily antiemetic dose into 2 doses on days when carboplatin is administered. Prophylactic antiemetic therapy with a serotonin antagonist is recommended [28] [29] [30] but may not be required in all patients. One group suggests that the addition of a neurokinin (NK 1 ) antagonist may be appropriate in some patients. 28 One of the following regimens given 30 minutes prior to therapy is recommended: 1. Ondansetron 8 mg to 16 The antiemetic therapy should continue for at least 3 days. A meta-analysis of several trials of serotonin antagonists recommends against prolonged (>24 hours) use of these agents, making a steroid, or steroid and dopamine antagonist combination, most appropriate for follow-up therapy. 33 One of the following regimens is recommended: Patients who experience signifi cant nausea or vomiting with one of these regimens should receive an agent from a different pharmacologic category. [13] [14] [15] [16] There is no evidence that substituting granisetron for ondansetron in subsequent treatment cycles, or increasing the dose, even to very high doses, is effective. This approach is not recommended. [34] [35] [36] [37] [38] B. Breakthrough Nausea and Vomiting [27] [28] [29] [30] : Patients should receive a prescription for an antiemetic to treat breakthrough nausea. One of the following regimens is recommended: 40 Routine prophylactic premedications should be given prior to paclitaxel administration. One of the following regimens is suggested 41 : 1. Ranitidine 150 mg 2. Dexamethasone 10 mg or 20 mg 3. Diphenhydramine 50 mg All given PO over 30 minutes prior to paclitaxel. 1. Ranitidine 50 mg 2. Dexamethasone 10 mg or 20 mg 3. Diphenhydramine 50 mg All given IV over 30 minutes prior to paclitaxel. E. Hematopoietic Growth Factors: Accepted practice guidelines and pharmaco economic analysis suggest that an antineoplastic regimen have a greater than 20% incidence of febrile neutropenia before prophylactic use of colony stimulating factors (CSFs) is warranted. For regimens with an incidence of febrile neutropenia between 10% and 20%, use of CSFs should be considered. For regimens with an incidence of febrile neutropenia less than 10%, routine prophylactic use of CSFs is not recommended. 42, 43 Since febrile neutropenia (grade 3 or 4) was reported in only 2% of patients in the trials reviewed, prophylactic use of CSFs is not recommended. 3 CSFs should be considered if a patient experiences febrile neutropenia or grade 4 neutropenia in a prior cycle of paclitaxel, carboplatin, and trastuzumab.
MAJOR TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http:// evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf).
Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities but make, or consider making, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. A. Gastrointestinal: Diarrhea (grade 1 or 2) 33%, 9 (grade 3) 5% 9 ; nausea (grade 1 or 2) 33%, 9 (grade 3) 8% 9 ; vomiting (grade 1 or 2) 30%, 9 (grade 3) 5% to 8%. 3,9 B . Hematologic: Anemia (grade 1 or 2) 70%, 9 (grade 3) 6% to 8% 3, 9 ; febrile neutropenia 2% 3 ; leukopenia (grade 3) 27% to 31% 3, 7 ; neutropenia (grade 1 or 2) 78%, 9 (grade 3) 20% to 42%, 3, 7, 9 (grade 4) 5% to 10% 3,7,9 ; thrombocytopenia (grade 1 or 2) 10%, 9 (grade 3) 3% to 4%. 3 1. CBC with differential C. Recommended Pretreatment Values: The minimally acceptable pretreatment CBC values required to begin a cycle with full-dose therapy in the protocols reviewed were: 1. Hemoglobin: Greater than or equal to 10 g/ dL. 7,9 2. Absolute neutrophil count (ANC): Greater than or equal to 1,500 cells/mcL. 3,7,9 3. Platelet count: Greater than or equal to 100,000 cells/mcL. 3,7,9 4 . Serum creatinine: a. Less than or equal to 1.5 times the upper limit of normal (ULN). 3 b. Less than 110 micromol/L. 7 c. Creatinine clearance greater than or equal to 65 mL/min. 9 
Serum bilirubin:
a. Greater than or equal to 1.25 times the ULN. 9 b. Greater than or equal to 1.5 times the ULN. 3, 7 6. AST/ ALT: a. Less than 1.5 times the ULN. 7 b. Less than 2.5 times the ULN. 9 c. Less than or equal to 3 times the ULN. 3 d. Less than 5 times the ULN in patients with hepatic involvement. 3 In clinical practice, a pretreatment ANC of 1,000 cells/mcL and platelets of 75,000 cells/ mcL are usually considered acceptable.
DOSAGE MODIFICATIONS
A. Renal Function 1. Paclitaxel: No adjustment is required. 44, 45 2. Carboplatin: a. Use a pharmacokinetic formula to calculate the dose. 45 b. CrCl: If the dose is based on body surface area rather than a pharmacokinetic formula: 46 1) Less than or equal to 50 mL/min and greater than or equal to 10 mL/min, reduce dose by 50%. 2) Less than 10 mL/min, reduce dose by 75%. B. Liver Function 1. Paclitaxel: a. Bilirubin less than 1.5 mg/dL and/or ALT/ AST greater than 2 times the ULN, reduce the dose by 25%. 47,48 b. Bilirubin greater than or equal to 1.6 mg/ dL and less than or equal to 3 mg/dL, reduce dose by 60%. 47,48 c. Bilirubin greater than 3 mg/dL, reduce dose by 75%. 47,48 d. Bilirubin greater than 5 times the ULN and/or ALT/AST greater than or equal to 10 times the ULN, do not give the drug. 44 2. Carboplatin: No adjustment is required. 44 
C. Myelosuppression
1. ANC less than 1,500 cells/mcL or platelet count less than 100,000 cells/mcL, delay treatment for a maximum of 2 weeks. 9 2. Grade 4 neutropenia, grade 3 or 4 febrile neutropenia or sepsis and grade 4 thrombocytopenia, maximum of 2 dose reductions allowed. 3 a. Paclitaxel: Reduce dose from 80 mg/m 2 to 70 mg/m 2 and then to 60 mg/m 2 . b. Carboplatin: Reduce dose from an AUC of 2 mg/mL per minute to 1 mg/mL per minute and then discontinue.
